With outstanding accuracy, great design and highly intuitive testing methods. Our first suite of products are on course to become the best-in-class for infectious respiratory diagnostics.
LEGIO X™ COVID-19
A COVID-19 lateral flow test, demonstrating the power of GeminaChem technology
LEGIO X™ is a COVID-19 rapid antigen test.
A lateral flow immunoassay that demonstrates the power of GeminaChem technology, delivering compelling sensitivity from anterior (shallow) nasal mucus, rather than the more invasive nasopharyngeal samples.
CE Mark approval in May 2022, just a few months after commencement of our development programme.
LEGIO X™ is housed in our premium cassette and the full kit became available for distribution in early 2023.
LEGIO X™ Influenza AB
Influenza AB multiplex lateral flow test - coming soon
LEGIO XI™ is our first multiplex device that can detect and distinguish between influenza types A and B with no cross reactivity.
Optimisation phase testing showed high levels of sensitivity with a considerable reduction in the amount of antibody usage compared to conventional chemistry platforms.
Future LEGIO diagnostics products
LEGIO products in development include:
Respiratory Syncytial Virus
We are in regular dialogue with senior medical advisors so that we are able to quickly switch test development to cover other, or new infectious respiratory diseases.